Lv1
10 积分 2023-03-18 加入
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
11小时前
待确认
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group
11天前
已完结
Olverembatinib and high-dose methotrexate in acute lymphoblastic leukemia: delayed methotrexate clearance and increased nephrotoxicity
24天前
已完结
Analysis of efficacy and long-term toxicity in the treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by limited radiotherapy
1个月前
已完结
Pirtobrutinib: First Approval
1个月前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
1个月前
已完结
Remibrutinib in Chronic Spontaneous Urticaria
2个月前
已完结
From Breakthroughs to Blueprints: Evolving Evidence and Future Directions in Relapsed and Refractory Large B-Cell Lymphoma
2个月前
已关闭
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy
2个月前
已完结
Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing–Neel Syndrome
2个月前
已完结
皖公网安备34019202002308
